Improvement after a supplement is not the same as a comparative result
Start with the comparison. A before-and-after change alone cannot isolate the contribution of an ingredient.
Inositol
Selected research topic
Women's health
Some measured outcomes improved in human comparison studies. Read these findings with their populations and conditions.
Findings from a combination study cannot be attributed to this ingredient alone.
Some findings concern patients or people with a deficiency.
- Publications for this topic
- 16
- Human comparison publications
- 1
- Publications needing review
- 10
Findings in the studies
serum free testosterone
- A better result than the comparison group was reported.Patient group · Single ingredient · 6 to 8 weeks
Measurement and study conditions
- Study type
- Randomized controlled trial: subjects were randomly assigned to groups for comparison.
- Study population
- Human participants · Patient group
- Ingredients tested
- Single ingredient
- How results were compared
- Results were compared between groups. · Study comparison: D-chiro-inositol versus placebo
- Additional measurement information
- Secondary outcome
- Measurement time
- 6 to 8 weeks
cycle length
Other human research, including observational studies and reviews
- A change was reported before and after use. Its cause cannot be isolated.
Several ingredients were tested together, so this ingredient’s individual effect is unknown.
Patient group · Combination study · 6 monthsMeasurement and study conditions
- Study type
- Randomized controlled trial: subjects were randomly assigned to groups for comparison.
- Study population
- Human participants · Patient group
- Ingredients tested
- Ingredient combination
- How results were compared
- Changes within the same group were compared. · Study comparison: within-arm baseline-to-6-month cycle length decrease in MI+DCI arm; CHC arm also decreased, no betwe
- Additional measurement information
- Secondary outcome
- Measurement time
- 6 months
incidence of gestational hypertension
Other human research, including observational studies and reviews
- A change was reported, but the comparison could not be confirmed.Patient group · Single ingredient · pregnancy; durations varied
Measurement and study conditions
- Study type
- Meta-analysis
- Study population
- Human participants · Patient group
- Ingredients tested
- Single ingredient
- How results were compared
- Study comparison: Pooled review/meta-analysis result as reported; abstract result sentence does not identify the compa
- Additional measurement information
- Secondary outcome
- Measurement time
- pregnancy; durations varied
regular menstrual cycles
Other human research, including observational studies and reviews
- A change was reported before and after use. Its cause cannot be isolated.
Several ingredients were tested together, so this ingredient’s individual effect is unknown.
Patient group · Combination study · 6 monthsMeasurement and study conditions
- Study type
- Other evidence
- Study population
- Human participants · Patient group
- Ingredients tested
- Ingredient combination
- How results were compared
- Changes within the same group were compared. · Within-group comparison
- Additional measurement information
- Secondary outcome
- Measurement time
- 6 months
Other measured outcomes (3)
Clinical pregnancy rate
Research with unclear study subject or type
- A change was reported, but the comparison could not be confirmed.Single ingredient
Measurement and study conditions
- Study type
- Meta-analysis
- Study population
- Recorded population category: Patient group. Whether the research involved humans needs confirmation.
- Ingredients tested
- Single ingredient
- Measurement time
- Not confirmed.
hypertensive disorders of pregnancy
Research with unclear study subject or type
- The study reported improvement in this measurement.
Measurement and study conditions
- Study type
- Meta-analysis
- Study population
- Recorded population category: Patient group. Whether the research involved humans needs confirmation.
- Ingredients tested
- Unknown intervention
- How results were compared
- Results were compared between groups. · Study comparison: Myo-inositol regimens versus no treatment, placebo, or another intervention on hypertensive disorder
- Additional measurement information
- Primary outcome
- Measurement time
- Antenatal pregnancy; trial timing and dose varied
regular menstrual cycle
Research with unclear study subject or type
- The study reported improvement in this measurement.
Measurement and study conditions
- Study type
- Meta-analysis
- Study population
- Recorded population category: Patient group. Whether the research involved humans needs confirmation.
- Ingredients tested
- Unknown intervention
- How results were compared
- Results were compared between groups. · Study comparison: inositol versus placebo; non-inferiority versus metformin also reported
- Additional measurement information
- Primary outcome
- Measurement time
- Not confirmed.
This result is held for interpretation. That does not mean research found no effect.
Outcome groups needing additional review (8)
- decreases in fT · Distinct papers needing additional review: 1Evidence criteria check: 1
- large-for-gestational-age infant · Distinct papers needing additional review: 1Direction unclear: 1
- Menstrual cycle regularity · Distinct papers needing additional review: 1Evidence criteria check: 1
- pregnancies · Distinct papers needing additional review: 1Applicability check needed: 1
- pregnancy · Distinct papers needing additional review: 1Evidence criteria check: 1
- spontaneous ovulation · Distinct papers needing additional review: 1Evidence criteria check: 1
- symptomatic relief · Distinct papers needing additional review: 1Evidence criteria check: 1
- total testosterone · Distinct papers needing additional review: 1Direction unclear: 1
One paper can appear under multiple measured outcomes or review reasons, so these counts should not be added together.
Representative outcome and study details
Studies with an unspecified organism reported a change with no confirmed comparison group in Clinical pregnancy rate.
Single-ingredient studies · Includes patient groups · comparator not confirmed
1 publications linked to this result
- Route, form, dose, or population details are incomplete, so the findings cannot be confirmed as directly comparable.
Data coverage and detailed study classifications
Paper counts are separated by research topic below. One paper may contribute to multiple findings.
Analysis status: Public-ready
Ingredient analysis date:
How the grade was determined: B
The 54.3 evidence score includes 0 independent human studies and 0 clinical studies in the representative benefit area. The B tier remains conservative because of limited repetition across independent human clinical studies, too few clinical findings with an explicit effect direction.
The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.
Papers linked to this ingredient overall: 101
Papers linked to this topic 16 · distinct papers 16 · papers with a confirmed human comparison 1 · papers needing additional review 10
A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.
- Clinical pregnancy rate: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- cycle length: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- decreases in fT: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- hypertensive disorders of pregnancy: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- incidence of gestational hypertension: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- large-for-gestational-age infant: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- Menstrual cycle regularity: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- pregnancies: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- pregnancy: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- regular menstrual cycle: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- regular menstrual cycles: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- serum free testosterone: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 1
- spontaneous ovulation: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- symptomatic relief: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- total testosterone: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
What the research found
cycle length
A change was reported before and after use. Its cause cannot be isolated.
Controlled study in people · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
Within-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
serum free testosterone
The study reported improvement in this measurement.
Controlled study in people · Single ingredient · Patient group
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
hypertensive disorders of pregnancy
The study reported improvement in this measurement.
Meta-analysis · Unknown intervention · Patient group
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
regular menstrual cycle
The study reported improvement in this measurement.
Meta-analysis · Unknown intervention · Patient group
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
regular menstrual cycles
A change was reported before and after use. Its cause cannot be isolated.
Other evidence · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
Within-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Clinical pregnancy rate
A change was reported, but the comparison could not be confirmed.
Meta-analysis · Single ingredient · Patient group
Analysis coverage and paper counts
1 paper · 1 measured outcome
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
incidence of gestational hypertension
A change was reported, but the comparison could not be confirmed.
Meta-analysis · Single ingredient · Patient group
Analysis coverage and paper counts
1 paper · 1 measured outcome
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
decreases in fT
The study needs further checking before its result can be interpreted.
Other evidence · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
Within-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
large-for-gestational-age infant
The study needs further checking before its result can be interpreted.
Meta-analysis · Unknown intervention · Patient group
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Menstrual cycle regularity
The study needs further checking before its result can be interpreted.
Controlled study in people · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
pregnancies
The study needs further checking before its result can be interpreted.
Controlled study in people · Single ingredient · Patient group
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
pregnancy
The study needs further checking before its result can be interpreted.
Controlled study in people · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
spontaneous ovulation
The study needs further checking before its result can be interpreted.
Review · Unknown intervention · Patient group
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
symptomatic relief
The study needs further checking before its result can be interpreted.
Review · Unknown intervention · Patient group
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
total testosterone
The study needs further checking before its result can be interpreted.
Other evidence · Single ingredient · Patient group
Within-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Unspecified measured outcome
The study needs further checking before its result can be interpreted.
Controlled human study · Unknown intervention · Unspecified population
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Unspecified measured outcome
The study needs further checking before its result can be interpreted.
Other evidence · Unknown intervention · Unspecified population
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
How to read research findings
How should I read research findings?
Research guidesNo clear difference and an uninterpretable result are different
A reported null comparison contains a result. An abstract without an interpretable comparison leaves a question unresolved.
Paper counts and study counts are different
Count original research separately from research that reanalyzes it. Publication volume is neither replication nor a quality rating.
Side effects and combination findings
Findings from this ingredient alone are shown separately from those involving another supplement or medication.
No reviewed caution rules are available yet. Reported caution findings are shown below.
Review 1 combination findings and 0 findings that outperformed an ingredient alone.
Findings to review with care
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Side effects reported with this ingredient alone
Symptoms or adverse events reported in studies without another active ingredient.
serum testosterone levels1 papers
In young adult female mice, DCIns at 5 mg/day increased serum testosterone and altered ovarian histology, while 10–20 mg/day reduced testosterone and caused age‑like ovarian lesions, indicating potential toxicity at higher doses.Animal studies · Animal studyReported improvements with combinations
Combination findings are grouped by how the study compared them. This is not a recommendation to combine ingredients.
Combinations with reported improvement
The combination showed improvement, but each ingredient's contribution is unclear.
SeleniumCombined administration of myo-inositol and selenium significantly decreased TSH, TPOAb, and TgAb levels and enhanced thyroid hormones compared to baseline.